Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study

Clinical Neurology and Neurosurgery

Volumn 168, Issue , 2018, Pages 1-6

  He, Yitao ^a   Cai, Zhili ^a   Zeng, Siling ^a   Chen, Siyan ^a   Tang, Bingshan ^a   Liang, Yubing ^a   Chang, Xin ^a   Guo, Yi ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Acute ischemic stroke; Blood glucose; Blood lipid; Blood pressure; Fluoxetine; Recurrence rate; Risk factor; Selective serotonin reuptake inhibitors

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; FLUOXETINE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANAPHYLAXIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG FATALITY; EPILEPSY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; KAPLAN MEIER METHOD; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SURVIVAL ANALYSIS; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; ADOLESCENT; AGED; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; COMPLICATION; DRUG EFFECT; RECURRENT DISEASE; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BRAIN ISCHEMIA; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; STROKE; TIME FACTORS; YOUNG ADULT;

EID: 85042480175     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2018.02.029     Document Type: Article

References (30)

1. Moretti, A., Ferrari, F., Villa, R.F., Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol. Ther. 146 (2015), 23–34.
2. Wang, M.T., Chu, C.L., Yeh, C.B., et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study. J. Clin. Psychiatry 76 (2015), e877–e885.
3. Erdur, H., Scheitz, J.F., Ebinger, M., et al. In-hospital stroke recurrence and stroke after transient ischemic attack: frequency and risk factors. Stroke 46 (2015), 1031–1037.
4. Heuschmann, P.U., Kircher, J., Nowe, T., et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur. J. Prev. Cardiol. 22 (2015), 1354–1362.
5. Wang, Y., Pan, Y., Zhao, X., et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation 132 (2015), 40–46.
6. He, Y.T., Tang, B.S., Cai, Z.L., et al. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. J. Stroke Cerebrovasc. Dis. 25 (2016), 771–780.
7. Tseng, Y.L., Chiang, M.L., Lane, H.Y., et al. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. Thromb. Res. 131 (2013), 325–332.
8. Bak, S., Tsiropoulos, I., Kjærsgaard, J., et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 33 (2002), 1465–1473.
9. Chen, Y., Guo, J.J., Li, H., et al. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann. Pharmacother. 42 (2008), 177–184.
10. Wu, C.S., Wang, S.C., Cheng, Y.C., et al. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am. J. Psychiatry 168 (2011), 511–521.
11. Mortensen, J.K., Larsson, H., Johnsen, S.P., et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 44 (2013), 420–426.
12. Caso, V., Santalucia, P., Pezzella, F.R., Depression and stroke risk. Womens Health (Lond.) 8 (2012), 35–37.
13. Trifiro, G., Dieleman, J., Sen, E.F., et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J. Clin. Psychopharmacol. 30 (2010), 252–258.
14. Lee, Y.C., Lin, C.H., Lin, M.S., et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J. Clin. Psychopharmacol. 33 (2013), 782–789.
15. Kunitz, S.C., Gross, C.R., Heyman, A., et al. The pilot stroke data bank: definition, design, and data. Stroke 15 (1984), 740–746.
16. Furie, K.L., Kasner, S.E., Adams, R.J., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 (2011), 227–276.
17. Mikami, K., Jorge, R.E., Adams, H.P. Jr., et al. Effect of antidepressants on the course of disability following stroke. Am. J. Geriatr Psychiatry 19 (2011), 1007–1015.
18. Mortensen, J.K., Andersen, G., Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients. Expert Opin. Drug Saf. 14 (2015), 911–919.
19. Chen, Y., Guo, J.J., Zhan, S., et al. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann. Pharmacother. 40 (2006), 2115–2122.
20. Beyazyüz, M., Albayrak, Y., Eğilmez, O.B., et al. Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study. Psychiatry Investig. 10 (2013), 148–154.
21. Ye, Z., Chen, L., Yang, Z., et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS One, 6, 2011, e21551.
22. Wilson, D.L., Ried, L.D., Identifying iatrogenic depression using confirmatory factor analysis of the center for epidemiologic studies depression scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. Res. Soc. Adm. Pharm. 8 (2012), 309–320.
23. Maurer-Spurej, E., Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell. Mol. Life Sci. 62 (2005), 159–170.
24. Côté, F., Fligny, C., Fromes, Y., et al. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 10 (2004), 232–238.
25. Ni, W., Watts, S.W., 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 33 (2006), 575–583.
26. Bymaster, F.P., Zhang, W., Carter, P.A., et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl.) 160 (2002), 353–361.
27. Schroeder, C., Tank, J., Boschmann, M., et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 105 (2002), 347–353.
28. Ducros, A., Boukobza, M., Porcher, R., et al. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 130 (2007), 3091–3101.
29. Verdel, B.M., Souverein, P.C., Meenks, S.D., et al. Use of serotonergic drugs and the risk of bleeding. Clin. Pharmacol. Ther. 89 (2010), 89–96.
30. Andrade, C., Sandarsh, S., Chethan, K.B., et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J. Clin. Psychiatry 71 (2010), 1565–1575.